September 7, 2021, Palo Alto, California – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs. The company will collaborate with I’rom Group Co., Ltd. (Japan) to make the service available for clients at every corner of the country. Using this as proof of concept,  I Peace plans to launch the iPSC banking service in the U.S. as the next phase of its business expansion. [Read more…]
Jacobio Enters Strategic Investment with Hebecell to Develop iPSC-derived NK Cell Therapy
BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 — Jacobio Pharmaceuticals (“Jacobio”, 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31. Jacobio will collaborate with Hebecell to develop the next-generation natural killer cell therapy based on induced pluripotent stem cells (iPSC-NK).
Once the deal is completed, Jacobio chairman and CEO Dr. Yinxiang Wang will be appointed as Chairman of Hebecell. [Read more…]
Orizuru Therapeutics Launches as R&D Company Focused on Clinical Application of iPSC-based Medicine
denovoMATRIX acquires state grant for accelerating development of iPSC scale-up technologies
DRESDEN, Germany, June 28, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, has received a grant from the State Bank of Saxony for the development of microcarriers designed for xeno-free induced pluripotent stem cell culture. The outlook for the technology is for applications in iPSC banking, allogenic therapies, as well as the clean meat industry.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies. The deal will enable Catalent to offer the building blocks to scale iPSC-based cell therapies while reducing barriers to entry to the clinic for therapeutic companies and is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have not been disclosed.
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 78
- Next Page »